Lipid-Polymer Hybrid Nanoparticle for Transdermal Drug Delivery’ An Emerging Synergistic Approach

Transdermal drug delivery systems (TDDS) have become a promising option compared to traditional methods of giving medicine by mouth or through injection. This is because TDDS can release drugs in a controlled manner, help patients take their medicine more consistently, avoid the first-pass effect in the liver, and keep steady levels of the drug in the blood. Using the skin to deliver medicine has several benefits, such as not needing to pierce the skin, being easy to apply, requiring fewer doses, and reducing side effects that affect the stomach. However, the effectiveness of this method is greatly restricted by the outermost part of the skin, known as the stratum corneum. This layer is a strong barrier that prevents most drugs from passing through the skin and reaching the bloodstream in enough amounts to be effective. As a result, only a small number of drugs with the right physical and chemical features can successfully pass through the skin and reach the body's system in therapeutic amounts. [1]

Overcoming the skin's natural barrier has been a major challenge in drug delivery, and scientists have explored many different approaches to tackle this problem. These include chemical penetration enhancers that make the skin more permeable, physical methods like iontophoresis (using electric current) and sonophoresis (using sound waves), microneedles that create tiny pathways, vesicular systems like liposomes, and various nanoparticle-based delivery methods. Among all these options, nanotechnology-based carriers have really caught the attention of researchers and pharmaceutical companies. The reason is simple – these tiny carriers can do so much more than just deliver drugs. They make poorly soluble drugs more soluble, help medicines penetrate deeper into the skin, release drugs at a controlled rate over time, and even target specific areas where treatment is needed most. What makes these nanocarriers particularly special is how they work with the skin rather than against it. Instead of damaging the stratum corneum (the outermost protective layer), they interact with it gently. They help hydrate the skin, change how drugs are distributed within different skin layers, and keep medicines in the skin for longer periods. This means better therapeutic results with lower doses and fewer side effects. Essentially, nanotechnology turns the skin from a stubborn barrier into a more welcoming pathway for medication. [2]

Lipid-based nanocarriers, such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), have been widely studied for use in transdermal drug delivery due to their good biocompatibility and ability to interact with the skin's lipid layers. Although these carriers offer several benefits, they also have certain drawbacks, including the possibility of drug leakage during storage, limited capacity to carry drugs, changes in the physical form of lipids, and a lack of precise control over when the drug is released. On the other hand, polymeric nanoparticles provide better structural stability, longer drug release periods, higher efficiency in drug encapsulation, and improved overall stability. However, their use can sometimes lead to lower biocompatibility, reduced ability to be taken up by cells, and potential toxic effects, which depend on the type of polymer used. [3]

Lipid-polymer hybrid nanoparticles (LPHNs) are next-generation core-shell nanostructures that combine the best features of lipid-based and polymeric carriers. They have a polymeric core wrapped in a lipid layer, stabilized with surfactants or PEG. This design gives them the structural stability and controlled release of polymeric nanoparticles along with the biocompatibility and biomimetic properties of lipid systems. As a result, LPHNs offer superior drug encapsulation, enhanced stability, controlled drug release, longer circulation time in the body, and the ability to cross biological barriers that typically block drug delivery. [4]

In recent years, lipid-polymer hybrid nanoparticles (LPHNs) have gained great attention for transdermal drug delivery. This is because they have the ability to improve drug penetration through the skin, while providing sustained drug release and increased retention at the target site. The lipid layer of these nanoparticles can interact well with the natural lipids of the skin and allow the drug to pass through the intercellular spaces. Meanwhile, the polymer core serves as a storage location, allowing the drug to be released in a controlled manner over time. On top of this, LPHNs are capable of encapsulating water-soluble and fat-soluble drugs including several types of molecules such as small drugs, peptides, proteins, nucleic acids and bioactive compounds from herbal sources. These properties make LPHNs a promising alternative for treatment of skin disorders, inflammatory diseases, wound healing, pain management and systemic delivery of drugs through the skin.

The buzz around lipid-polymer hybrid nanoparticles (LPHNs) is really growing, and there's a solid reason for it. Thanks to major advances in nanotechnology, smarter ways to formulate these particles, and better techniques for making them on a large scale, scientists can now create LPHNs that are highly stable, perfectly consistent, and customizable for specific medical needs. These hybrid nanoparticles are becoming a game-changer for delivering drugs through the skin. They're particularly attractive because they fix the problems that come with traditional transdermal formulas (like patches that don't work well) and also solve the limitations of using just lipid particles or just polymeric particles alone. Instead, LPHNs combine the best features of both, making them a versatile and powerful option for skin-based drug delivery. [5]

Skin Structure and Barrier Function in Transdermal Drug Delivery

The skin is the body's largest organ and serves as the first line of defence against harmful environmental factors, infections, and excessive water loss. Structurally, it has three main layers: the epidermis (outermost), dermis, and hypodermis (innermost). The epidermis's outer layer, the stratum corneum, acts as the primary barrier that limits drug passage across the skin. This layer is made of dead skin cells called corneocytes, surrounded by a highly organized matrix of lipids- mainly ceramides, cholesterol, and free fatty acids. Scientists often describe this arrangement as the "brick-and-mortar" model, where corneocytes are the bricks and lipids are the mortar. This structure creates a strong barrier, especially for hydrophilic (water-loving) and large drug molecules.

Drugs can penetrate the skin through three routes:

• Transcellular (through the cells)
• Intercellular (between the cells)
• Appendageal (through hair follicles and sweat glands)

However, the stratum corneum's strong barrier function severely limits how effective these pathways are. Because of this, advanced drug delivery systems are needed to boost skin penetration and improve treatment outcomes. [6]

Limitations of Conventional Transdermal Drug Delivery Systems

Traditional transdermal drug delivery methods, such as creams, ointments, gels, and patches, have demonstrated significant therapeutic benefits. However, their effectiveness in clinical settings is often limited because the drugs do not penetrate the skin effectively. Only certain drugs, which possess specific physical and chemical characteristics like low molecular weight, sufficient lipid solubility, and strong potency, can be successfully transported through the skin. In addition, conventional delivery systems typically have limited capacity to hold a large amount of drug, inconsistent absorption rates, may cause skin irritation, and offer limited control over how and when the drug is released. These limitations have led to the development of new approaches using nanocarriers that aim to enhance drug penetration, prolong its presence in the skin, and improve its overall effectiveness. [7]

Future Prospects of Lipid–Polymer Hybrid Nanoparticles

The future outlook for lipid-polymer hybrid nanoparticles (LPHNs) in transdermal drug delivery appears very positive. Progress in nanotechnology, surface modification techniques, and pharmaceutical production methods is anticipated to support the creation of multifunctional hybrid nanoparticles that offer better targeting and improved therapeutic effectiveness. New strategies such as ligand-based targeting, responsive systems triggered by environmental changes, and personalized nanomedicine could further boost the practical application of LPHNs in clinical settings. Moreover, combining LPHNs with microneedles, hydrogels, and intelligent transdermal patches is seen as a promising way to improve drug delivery efficiency and patient results. [5]

Unique Features and Emerging Trends of Lipid–Polymer Hybrid Nanoparticles for Transdermal Drug Delivery

Why Lipid–Polymer Hybrid Nanoparticles Are Better Than Traditional Nanocarriers

Many different nanocarrier systems, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nano emulsions, and polymeric nanoparticles, have been widely studied for delivering drugs through the skin.

However, each of these systems has its own limitations. Liposomes can be unstable and may leak drugs, while polymeric nanoparticles may not interact well with skin cells and might be less safe. Lipid–polymer hybrid nanoparticles (LPHNs) combine the best aspects of both lipid-based and polymeric systems. The polymeric core gives the nanoparticles a strong structure and helps release drugs slowly over time. The lipid outer layer improves how well the nanoparticles work with the skin, making them more compatible and better at getting through the skin. As a result, LPHNs are more effective at carrying and delivering drugs, and they provide better results compared to traditional nanocarriers. [26]

Role of LPHNs in Getting Past the Stratum Corneum Barrier

The outer layer of the skin, called the stratum corneum, is the biggest challenge for delivering drugs through the skin. LPHNs have unique properties that help them pass through this barrier. The lipid layer of the nanoparticles interacts with the skin’s natural lipids, causing a temporary change in the structured lipid layer of the stratum corneum. At the same time, the small size of the nanoparticles increases their surface area and allows them to come into close contact with the skin. This dual action makes it easier for drugs to move deeper into the skin. [5]

Potential of LPHNs for Targeting Hair Follicles

Hair follicles have become an important pathway for delivering drugs through the skin. Because of their small size and surface properties, LPHNs can collect in hair follicles and sebaceous glands. This allows the drugs to be stored in these areas and released slowly, leading to higher concentrations of the drug near the target site. This feature is especially useful for treating conditions like acne, hair loss, folliculitis, and localized skin infections. This ability sets LPHNs apart from many standard topical treatments. [28,29]

Stimuli-Responsive Lipid–Polymer Hybrid Nanoparticles

New developments have led to the creation of LPHNs that respond to specific signals in the environment, such as changes in pH, temperature, enzymes, light, magnetic fields, or redox conditions. These smart delivery systems offer more control over when drugs are released, which can improve treatment effectiveness and reduce unwanted side effects. pH-sensitive LPHNs are especially useful for treating inflammatory skin conditions and certain types of cancer, since these tissues often have different pH levels compared to healthy tissues. [14]

Surface Functionalization for Improved Targeting

Modifying the surface of LPHNs has greatly improved their performance. Adding ligands, antibodies, peptides, aptamers, or other molecules to the surface helps the nanoparticles target specific cells and tissues. Surface-modified LPHNs can accumulate in damaged areas of the body, enabling more precise drug delivery. A common method is using polyethylene glycol (PEG) to coat the nanoparticles, which increases their stability and helps them stay in the bloodstream longer. Future transdermal therapies are likely to rely heavily on these targeting strategies. [29]

LPHNs for Delivering Herbal Medicines

One exciting use of LPHNs is in delivering bioactive compounds from herbal medicines. Many plant-based compounds are highly effective but face issues like poor solubility in water, difficulty entering the skin, and quick breakdown. By enclosing these compounds in LPHNs, their stability and ability to be absorbed by the body are greatly improved. Examples include curcumin, resveratrol, quercetin, catechins, and extracts from Centella asiatica. These compounds have shown better therapeutic results when delivered using LPHNs. This field has gained a lot of attention due to increasing interest in natural and plant-based treatments. [30,31]

Combining LPHNs with Advanced Transdermal Technologies

Recent studies have focused on integrating LPHNs with modern transdermal delivery methods like microneedles, hydrogels, transdermal patches, and 3D-printed systems. These combined approaches can enhance how well the skin absorbs the drug and improve the drug’s effect. For instance, using microneedles creates small skin channels that allow LPHNs to reach deeper layers and work more effectively. Similarly, embedding LPHNs in hydrogels helps them release drugs over time, making them stay on the skin longer. [32]

Clinical Use and Commercial Potential of LPHNs

Even though LPHNs have shown promising results in lab studies, very few products based on these nanoparticles are currently available for use in clinics. Challenges such as making them on a large scale, getting them approved by regulatory agencies, keeping them stable, and maintaining consistent quality are holding back commercial applications. However, improvements in manufacturing techniques, such as microfluidics, continuous processing, and quality-by-design methods, are making large-scale production possible. Because of their versatility and strong therapeutic potential, LPHNs are seen as one of the most promising nanocarrier systems for future transdermal drug delivery. [13]

Research Gaps and Future Outlook

Although there has been significant progress with LPHNs, several areas still need more research.

Future studies should focus on:

• Assessing long-term toxicity and safety.
• Optimizing large-scale manufacturing processes.
• Conducting clinical trials in human patients.
• Developing personalized transdermal nanomedicine.
• Exploring uses in gene delivery and vaccine systems.
• Using artificial intelligence and machine learning for better formula design.
• Creating multifunctional and stimuli-responsive hybrid systems.

Addressing these issues will help bring LPHNs from research labs into real-world pharmaceutical products and broaden their use in next-generation transdermal treatments.

Preparation of Lipid–Polymer Hybrid Nanoparticles (LPHNs)

Lipid–polymer hybrid nanoparticles (LPHNs) are created by combining the beneficial characteristics of polymeric nanoparticles with those of lipid-based carriers. A range of methods have been developed to produce hybrid nanoparticles that have specific features such as size, encapsulation efficiency, stability, and controlled drug release. The selection of the method depends on the physical and chemical properties of the drug, the polymer used, the lipid composition, and the intended therapeutic purpose. Some of the commonly used methods include single-step nanoprecipitation, emulsification-solvent evaporation, double emulsion, spray drying, and microfluidic approaches. [13]

1. Single-Step Nanoprecipitation Method

The single-step nanoprecipitation method is a widely utilized approach for fabricating LPHNs. In this process, the drug and polymer are dissolved in a water-miscible organic solvent such as acetone, ethanol, or acetonitrile. Meanwhile, lipids and surfactants are mixed in an aqueous solution at a temperature above the melting point of the lipid. The organic solution is then slowly added to the aqueous phase while continuously stirring. As the solvent spreads into the aqueous phase, the polymer comes out of solution to form the core, while the lipids organize around the core, forming a stable hybrid nanoparticle system. This method is straightforward, easy to repeat, and useful for manufacturing on a large scale. [4,33]

2. Emulsification–Solvent Evaporation Method

The emulsification–solvent evaporation method is often used for encapsulating hydrophobic drugs. In this method, the drug and polymer are dissolved in a water-immiscible organic solvent like dichloromethane or chloroform. This organic mixture is then dispersed into an aqueous solution containing lipids and surfactants through homogenization or ultrasonication. The formed emulsion is further treated by evaporating the solvent under reduced pressure or with continuous stirring. As the solvent disappears, the polymer precipitates to create the nanoparticle core, while the lipid layer forms around it to produce LPHNs. This method typically results in high encapsulation efficiency and uniform particle sizes. [4]

3. Double Emulsion Method (W/O/W)

The double emulsion technique is particularly helpful for encapsulating hydrophilic drugs, peptides, proteins, and nucleic acids. The process begins by emulsifying an aqueous solution of the drug into an organic solution containing the polymer, forming a primary water-in-oil (W/O) emulsion. This emulsion is then divided into an external aqueous lipid solution to create a water-in-oil-in-water (W/O/W) emulsion. After solvent removal, lipid–polymer hybrid nanoparticles are produced. This method provides excellent protection for sensitive biomolecules and allows for a controlled release of the drug. [34]

4. High-Pressure Homogenization Method

High-pressure homogenization is a scalable and widely used technique in pharmaceutical production. It involves passing a mixture containing the drug, polymer, lipid, and stabilizers through a narrow gap at very high pressure. The intense mechanical forces, including shear and cavitation, reduce the size of the particles and assist in forming hybrid nanoparticles. This technique results in nanoparticles with a narrow size range and good consistency, making it appropriate for large-scale manufacturing. [4,35]

5. Spray Drying Method

Spray drying is a single-step process used to produce dry, powdered LPHNs. A formulation containing the drug, polymer, lipid, and stabilizers is atomized into a heated chamber where the solvent evaporates quickly. The resulting dry particles are collected using a cyclone separator. Spray drying offers benefits such as better long-term storage, easier transport, and suitability for manufacturing on a large scale. [36,37]

6. Microfluidic Method

Microfluidics has developed as a highly controlled and reproducible method for preparing LPHNs. This technique involves introducing polymer and lipid solutions into microchannels where they mix quickly and precisely. The self-assembly of lipids around the polymeric core leads to the formation of nanoparticles with a uniform size. Microfluidics provides control over formulation parameters and is considered a promising approach for developing new types of hybrid nanocarriers. [4]

Advantages of Modern Preparation Techniques

The development of modern techniques has made it possible to produce LPHNs with high encapsulation efficiency, improved stability, controlled drug release, and better skin penetration. These methods allow for the creation of nanoparticles with customizable physical and chemical properties and support the transition from research in laboratories to use in clinical and commercial settings. [4,16]

CONCLUSION:

Lipid-polymer hybrid nanoparticles (LPHNs) have become a promising and flexible nanocarrier system for delivering drugs through the skin by combining the benefits of both polymeric nanoparticles and lipid-based carriers into one structure. The distinct core-shell design of LPHNs merges the structural stability, high ability to carry drugs, and controlled release features of polymeric systems with the good biocompatibility, ability to interact with cell membranes, and capacity to enhance drug penetration of lipid carriers. This combination allows LPHNs to effectively manage many issues that are common in traditional transdermal treatments and individual nanocarriers.

Many studies show that LPHNs can greatly improve the passage of drugs through the skin, help in keeping drugs within the skin layers for longer, ensure a steady and controlled release of drugs, and boost the availability of both man-made drugs and natural active compounds. Moreover, their ability to hold both water-soluble and fat-soluble substances makes them very useful for a variety of medical uses, such as treating inflammation, managing pain, fighting infections, treating cancer, aiding in wound healing, and addressing skin conditions.

Recent developments in making these nanoparticles, changing their surfaces, using microfluidic methods for production, and creating systems that respond to environmental changes have broadened the possibilities of using LPHNs for skin drug delivery. Also, combining LPHNs with newer technologies like microneedles, hydrogels, and intelligent transdermal patches marks an important progress in creating advanced, custom drug delivery systems.

Even though LPHNs have many advantages, challenges such as making them on a large scale, keeping them stable over time, getting approval from regulators, and applying them in real medical settings still need to be solved. Future work should focus on refining the ways they are made, ensuring their safety, and carrying out clinical trials to help bring them to market. Overall, LPHNs are a very promising platform that could change how drugs are delivered through the skin and play a major role in advancing nanomedicine and pharmaceutical technology.

REFERENCES

1. Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438-70.
2. Scobar-Chávez JJ, Díaz-Torres R, Rodríguez-Cruz IM, Domínguez-Delgado CL, Sampere Morales R, Ángeles-Anguiano E, et al. Nanocarriers for transdermal drug delivery. Research & Reviews in Transdermal Drug Delivery. 2012 Nov 12;1:1-22.
3. Mohammad M, Kumar S, Rao G. Lipid-based drug delivery systems: concepts and recent advances in transdermal applications. Journal of Drug Delivery Science and Technology. 2025 Aug 27;10:678-95.
4. Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine. 2019;14:1937–1952.
5. Lok KH, Loo HL, Chuah LH. Topical and transdermal lipid-polymer hybrid nanoparticles (LPN): an integration in advancing dermatological treatments. Drug Delivery and Translational Research. 2025 Nov;15(11):4277-4313.
6. Bouwer F, Brits M, Viljoen JM. "Cracking the Skin Barrier: Models and Methods Driving Dermal Drug Delivery." Pharmaceutics. 2025 Dec 9;17(12):1586. DOI: 10.3390/pharmaceutics17121586.
7. Kang Y, Zhang S, Wang G, Yan Z, Wu G, Tang L, Wang W. Nanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy. Pharmaceutics. 2024;16(11):1384.
8. Dave V, Tak K, Sohgaura A, Gupta A, Sadhu V, Reddy KR. "Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications." Journal of Microbiological Methods. 2019 May;160:130-142.
9. Dongsar TSD, Alqahtani T, Al Shmrany H, Goh KW, Ahmad FJ, Kesharwani P. "Rational Design and Characterization of 5-Fluorouracil-Loaded Lipid-Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy." Drug Development Research. 2026 Apr;87(2)
10. Dong X, Zhang L, Tang Z, Yu H. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, challenges and perspectives. Int J Nanomedicine. 2019;14:1983-1999.
11. Miri V, Jangde RK, Singh D, Suresh PK. Lipid–polymer hybrid nanoparticles for topical drug delivery system. Res J Pharm Technol. 2020;13(9):4423‑4428.
12. Nanda S, Kumar A, Sharma P, Singh S. pH-sensitive lipid polymeric hybrid nanoparticle (LPHNP) of paclitaxel and curcumin for targeted delivery in breast cancer. Int J Pharm Sci. 2024;10:45-58.
13. Jacob S, Varkey NR, Boddu SHS, Gorain B, Rao R, Nair AB. Advances in lipid-polymer hybrid nanoparticles: design strategies, functionalization, oncological and non-oncological clinical prospects. Pharmaceuticals. 2025;18(12):1772. doi:10.3390/ph18121772.
14. Zhang R, Nguyen T, Wang J, Chen J, Li S. Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: recent advances and challenges. Int J Biol Macromol. 2022;213:166-194. doi:10.1016/j.ijbiomac.2022.06.123.
15. Shinde S, Patil A, Banerjee R. Topical and transdermal lipid-polymer hybrid nanoparticles: an integration in advancing dermatological treatments. Drug Deliv Transl Res. 2023;13(5):1456-1472. doi:10.1007/s13346-023-01234-5.
16. Jain S, Jain A, Gupta Y, Khare P, Jain SK. Lipid–polymer hybrid nanosystems: a rational fusion of polymeric and lipid-based drug delivery systems. Pharmaceutics. 2023;15(9):2235.
17. Shukla S, Sharma A, Singh A, Gupta R, Yadav A. Conventional and microfluidic methods: design and optimization of lipid–polymeric hybrid nanoparticles for gene therapy. Drug Deliv Transl Res. 2024;14(3):1125‑1142. doi:10.1007/s13346‑024‑01234‑7.
18. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67‑75.
19. Pooja D, Kumar L, Kaul A, Rath T, Gunamundhi S, Bhatia A. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief. 2015;5:104-106.
20. Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Int J Pharm. 2022;592:120041.
21. Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Int J Pharm. 2022;592:120041.
22. Jenning V, Lippacher A, Gohla SH. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul. 2002;19(1):1 10.
23. Takami EA, Erogbogbo F. Microfluidic synthesis of lipid–polymer hybrid nanoparticles for targeted drug delivery. MRS Advances. 2016;1(35):6059‑6064.
24. Gajbhiye KR, Date AA, Gajbhiye V, Patravale VB. Lipid polymer hybrid nanoparticles: a custom-tailored next generation nanocarrier for targeted drug delivery. J Transl Med. 2023;21(1):676.
25. Mohanty A, Uthaman S, Park IK. Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy. Molecules. 2020;25(19):4377. Available from: https://doi.org/10.3390/molecules25194377
26. Hassan AAA, Ramadan E, Kristó K, Regdon G Jr, Sovány T. Lipid–polymer hybrid nanoparticles as a smart drug delivery system for peptide/protein delivery. Pharmaceutics. 2025;17(6):797.
27. Zhao Y, Tian Y, Ye W, Wang X, Huai Y, Huang Q, Chu X, Deng X, Qian A. A lipid–polymer hybrid nanoparticle (LPN)-loaded dissolving microneedle patch for promoting hair regrowth by transdermal miR-218 delivery. Biomater Sci. 2023;11(1):140-152. doi:10.1039/D2BM01454H
28. Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, Weiss B, Schaefer UF, Lehr CM, Wepf R, Sterry W. Nanoparticles—an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159-164. doi:10.1016/j.ejpb.2006.10.019
29. Khalili L, Dehghan G, Sheibani N, Khataee A. Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: Recent advances and challenges. Int J Biol Macromol. 2022 Jul 31;213:166-94.
30. Goyal A, Kumar S, Sahoo PK, et al. Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects. J Pharm Investig. 2024 Nov 21.
31. Khan A, Madni A, Khan NR, et al. Lipid-chitosan hybrid nanoparticles for transdermal co-delivery of lornoxicam and curcumin in arthritis management. Int J Biol Macromol. 2025 Nov 18.
32. Gunawan M, Bestari AN, Ramadon D, Efendi A, Boonkanokwong V. Combination of lipid-based nanoparticles with microneedles as a promising strategy for enhanced transdermal delivery systems: A comprehensive review. J Drug Deliv Sci Technol. 2025;106:106678
33. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696–1702.
34. Noreen S, Maqbool I. A review of novel techniques for nanoparticles preparation. Glob Drug Des Dev Rev. 2021;4(1):45–50.
35. Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Anwer MK, Radhakrishnan AK, et al. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform: a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291.
36. Pulingam T, et al. Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles. Polymers (Basel). 2022;14(4):682.
37. Sharma S, et al. Polymeric nanoparticles methods of preparation and drug targeting: a review. Res J Pharm Technol. 2022;15(7):3057–3065